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In their Letter to the Editor in this issue, Garcia-
Montojo, Li and Nath [5] question several technical
aspects of our study recently published in Acta Neuro-
pathologica Communications [6]. Our study, in contrast
to an earlier report by Nath’s group [11], failed to find
elevated expression of HERV-K RNA in postmortem
premotor cortex of patients with amyotrophic lateral
sclerosis (ALS). Another study by an independent group
[12] also failed to confirm elevated expression of HERV-K
RNA in postmortem brain tissue of ALS patients.
There are a total of five technical issues raised by Garcia-
Montojo and colleagues in their Letter. Briefly, these are, i)
concerns regarding our selection of controls, in particular
the number of control subjects with cancer, ii) concerns
regarding the number of ALS patients investigated, iii)
concerns regarding the RNA integrity numbers (RINs) of
the ALS patient tissues and control tissues analysed in our
study, iv) concerns regarding our selection of reference
genes for RT-qPCR (quantitative real-time reverse
transcription polymerase chain reaction) for data
normalisation, and v) our use of the RT-qPCR tech-
nique rather than alternative methods such as RNA-
Seq (whole transcriptome shotgun sequencing by
next-generation sequencing) for analysing the post-
mortem tissue samples. Each of these questions will
be considered in turn:
The selection of controls
Garcia-Montojo and colleagues point out that nearly half
of our controls (11/23) had cancer, although none had
cerebral metastases. However, 25% of the controls in
their own study [11] also had cancer. The proportion of
controls with cancer is theoretically significant because
upregulation of HERV-K expression occurs in various
types of tumour tissue and it is conceivable that HERV-K
released into the circulation from such tumours might be
detected in the cerebral tissue of controls even in the
absence of cerebral metastases. We were fully aware of
this theoretical possibility when we conducted our study
and therefore reanalysed our data after exclusion of all
controls with cancer (see Additional file 1: Figure S11 of
Garson et al., [6] reproduced here). This reanalysis did not
alter the key conclusion of our study that patients with
ALS do not have higher levels of cerebral HERV-K RNA
expression than non-ALS controls. Garcia-Montojo and
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colleagues also raise the question of controls with cerebral
infarcts. It is true that 2 of our 23 controls had cerebral
infarcts (not affecting the premotor region analysed) and
that one of these, with an old infarct, had relatively high
levels of HERV-K RNA expression. However, the inclusion
of these two controls in our series did not significantly
influence the overall data or alter the conclusion that
patients with ALS do not have higher levels of cerebral
HERV-K RNA expression than non-ALS controls.
The number of ALS patients investigated
In their Letter, Garcia-Montojo et al. correctly point out
that ALS is a heterogeneous syndrome with variable
clinical phenotypes and the likelihood of several different
pathophysiological pathways. They argue that only a
subset of these different groups is associated with acti-
vation of transposable elements including HERVs and that
it is therefore important that a large enough sample size is
tested to capture the ALS patients in this subset. We agree
with this argument but it is a weakness of their own
study [11], in which HERV-K RNA expression was
measured in only 11 ALS patients, more than of ours
[6] in which HERV-K RNA expression was measured in
34 patients with ALS. By analysing more than three
times as many ALS patients we thereby minimised the
chance of missing the postulated subset with elevated
HERV-K RNA expression.
RNA integrity numbers (RINs)
RIN values are dependent upon measurements of elec-
trophoretically separated 28S and 18S ribosomal RNAs
and thus are not necessarily the most suitable measure
for assessing the quality of mRNA, which is the actual
target in RT-qPCR assays. A recent RT-qPCR study of
179 human brain samples [14] concluded that RIN is an
unreliable measure of RNA quality from postmortem
brain tissue. Other techniques which assess the quality
of mRNA more directly may be therefore be preferable
to use in this context [15]. Nevertheless, we elected to
assess RNA quality using RIN values in our study in
order to replicate as closely as possible the methods used
by Li et al. [11] in their HERV-K/ALS study. Garcia-
Montojo and colleagues question the RIN values of
some of the samples that we analysed, stating that “some
RIN values were as low as 5.” In fact only 2 of 57
samples had RIN values as low as 5 and the mean RIN
value was 6.3. There is a degree of controversy about the
minimum acceptable RIN but values of > 5 [4, 9] or > 3.95
[13] have been considered adequate for such studies. It
has also been reported that RNA quantification using
short amplicons of less than 250 bp, such as those
employed in our study, is virtually independent of RNA
quality as assessed by RIN values [4].
Garcia-Montojo and colleagues also point out that the
average RIN number was different between our ALS
patient samples and the non-ALS control samples,
however the magnitude of this difference was relatively
small, 6.53 and 6.05 respectively. Most importantly,
we did not find any correlation between RIN values
and GAPDH-normalised HERV-K RNA expression
(see Additional file 1: Figure S4 of Garson et al., [6]
reproduced here) and so do not consider this small
difference in average RIN values to be of significance
in interpreting the data.
The selection of reference genes for data
normalisation
The use of reference genes for RT-qPCR data normalisa-
tion is essential to control for differences in RNA quality
and quantity between samples. Reference genes to be
used in any particular study should be experimentally
validated to ensure that they are stably expressed in both
disease and control tissues as recommended by inter-
national guidelines (MIQE) [2]. Following experimental
validation we selected two reference genes, GAPDH and
XPNPEP1 as the most stably expressed of the nine can-
didate genes tested. One of these (GAPDH) had also
been used as reference gene by Li et al. [11]. It is there-
fore difficult to understand the criticism raised by
Garcia-Montojo and colleagues against the use of a
reference gene that they also selected for their own study
of HERV-K RNA expression in ALS postmortem brain,
and we strongly refute their assertion that it is “im-
possible to interpret the data”. We obtained essentially the
same result, i.e. a failure to confirm elevated expression of
HERV-K RNA in postmortem brain tissue of ALS
patients, whether data was normalised against GAPDH or
XPNPEP1. It is noteworthy that in an evaluation of 12
candidates [3] XPNPEP1 was identified as the most
suitable reference gene for use on postmortem brain tissue
in various neurological diseases, including ALS.
The authors of the Letter refer to a study by Rydbirk
et al. [13] to support their heterodox view that it is
better to select the least stable rather than the most stable
reference genes for normalisation of RT-qPCR data in this
type of study. However, Rydbirk and colleagues conclude
precisely the opposite of what Garcia-Montojo et al.
propose, stating that “we identified the most stable re-
ference genes to be UBE2D2, CYC1, and RPL13 which we
recommend for future RT-qPCR studies on human brain
tissue …” . Furthermore, they warn against the use of un-
stable reference genes “in order to avoid false results”.
With reference to the data reported by Rydbirk and
colleagues on GSK3B RNA expression levels in the brains
of Alzheimer’s and Parkinson’s disease patients, Garcia-
Montojo et al. cite several papers [1, 8, 10, 16] to support
their argument about the supposed benefit of using
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unstable reference genes to measure cerebral RNA levels
by RT-qPCR in neurodegenerative diseases. However, the
cited papers do not actually provide supportive evidence
because they report data on protein rather than on RNA,
or on peripheral blood cells rather than brain, or on
mouse rather than human, or on GSK3B splice isoform
ratios rather than RNA levels. Furthermore, some studies
report lower levels rather than higher levels of cerebral
GSK3B RNA in Alzheimer’s disease compared to normal
controls [7]. All of these points undermine their argu-
ments about the theoretical advantage of selecting
unstable reference genes.
The use of the RT-qPCR technique
The authors of the Letter also question whether the use
of the RT-qPCR technique to detect transcripts in
neurodegenerative diseases may not be ideal and that it
might be better to use RNA-Seq, (with or without laser
capture microdissection of neurons), since it controls for
a possible decrease in global transcriptional activity.
Alternatively, they suggest that detection of transcripts
by in situ hybridisation may be considered. The reason
that we elected to use the RT-qPCR technique in our
study was that we were aiming to provide independent
confirmation of the findings of Li et al. [11] using the
same techniques that they used in their study. Thus
we used the same RT-qPCR methods, including the
same reverse transcription technique, the same DNase
treatment method, the same PCR reagents, the same
reference gene (GAPDH), the same thermal cycling
parameters, the same 2-ΔΔCt data analysis method and
identical primer sets to those that they had employed.
By questioning the use of RT-qPCR in our study and
by asserting that “no reliable conclusion can be made”
from it, Garcia-Montojo and colleagues are thereby
also questioning their own study and the reliability of
their own conclusions.
In summary, the authors of the Letter raise a number of
questions about technical aspects of our study. We have
in this response robustly defended our technical methods
and conclusions but, to the extent that any of their argu-
ments may be valid, they apply equally to their own work.
Additional file
Additional file 1: Figure S11. (reproduced from Garson et al., [6]).
Relative expression levels of HERV-K gag, pol and env RNA in 34 ALS and
12 non-ALS controls without cancer. a, b, and c normalised against
GAPDH; e, f, and g normalised against XPNPEP1. Horizontal black lines rep-
resent geometric means. All p values are > 0.05, (no significant difference)
varying between 0.15 and 0.77. Figure S4. (reproduced from Garson et al.,
[6]). Lack of significant correlation between RNA integrity number (RIN) and
HERV-K gag, pol and env RNA relative expression levels. Data from all 34
ALS and 23 non-ALS controls are presented. a, b, c normalised
against GAPDH; R-squared coefficient of determination values calculated
in Microsoft Excel. Linear regression p values are shown in each graph.
(DOCX 111 kb)
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